News

SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials

Details

SNIPR BIOME, a leading CRISPR and microbiome private biotech company, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge and LSP, together with North-East Family Office and Wellington Partners. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient’s microbial community intact. 

Themis receives FDA fast track designation for Chikungunya vaccine candidate

Details

Themis announced today that the US Food and Drug Administration (FDA) has granted fast track designation to the Company’s lead vaccine candidate (MV-CHIK) for the prevention of Chikungunya, a debilitating disease with global outbreak potential. The program is the most advanced Chikungunya vaccine candidate and has already successfully completed Phase 2 clinical development with results recently published in The Lancet. 

Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

Details

Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers. IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced/ metastatic solid tumors. 

  1. AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
  2. Adrenomed closes €24 million financing led by Wellington Partners and HBM
  3. Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in "The Lancet"
  4. Themis announces exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies
© Wellington Partners, 2019.